Methods for neuroscience drug development: Guidance on standardization of the process for defining clinical outcome strategies in clinical trials
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Zaragoza Domingo, Silvia
- dc.contributor.author Alonso Caballero, Jordi
- dc.contributor.author Ferrer Forés, Maria Montserrat
- dc.contributor.author Yavorsky, Christian
- dc.date.accessioned 2024-06-06T06:08:09Z
- dc.date.available 2024-06-06T06:08:09Z
- dc.date.issued 2024
- dc.description.abstract Neurosciences clinical trials continue to have notoriously high failure rates. Appropriate outcomes selection in early clinical trials is key to maximizing the likelihood of identifying new treatments in psychiatry and neurology. The field lacks good standards for designing outcome strategies, therefore The Outcomes Research Group was formed to develop and promote good practices in outcome selection. This article describes the first published guidance on the standardization of the process for clinical outcomes in neuroscience. A minimal step process is defined starting as early as possible, covering key activities for evidence generation in support of content validity, patient-centricity, validity requirements and considerations for regulatory acceptance. Feedback from expert members is provided, regarding the risks of shortening the process and examples supporting the recommended process are summarized. This methodology is now available to researchers in industry, academia or clinics aiming to implement consensus-based standard practices for clinical outcome selection, contributing to maximizing the efficiency of clinical research.
- dc.format.mimetype application/pdf
- dc.identifier.citation Zaragoza Domingo S, Alonso J, Ferrer M, Acosta MT, Alphs L, Annas P, et al. Methods for neuroscience drug development: Guidance on standardization of the process for defining clinical outcome strategies in clinical trials. Eur Neuropsychopharmacol. 2024 Apr 3;83:32-42. DOI: 10.1016/j.euroneuro.2024.02.009
- dc.identifier.doi http://dx.doi.org/10.1016/j.euroneuro.2024.02.009
- dc.identifier.issn 0924-977X
- dc.identifier.uri http://hdl.handle.net/10230/60361
- dc.language.iso eng
- dc.publisher Elsevier
- dc.relation.ispartof Eur Neuropsychopharmacol. 2024 Apr 3;83:32-42
- dc.rights © 2024 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.subject.keyword Clinical trials
- dc.subject.keyword Drug development
- dc.subject.keyword Early trials
- dc.subject.keyword Endpoints
- dc.subject.keyword Outcome
- dc.title Methods for neuroscience drug development: Guidance on standardization of the process for defining clinical outcome strategies in clinical trials
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion